Dr. Reddy's Laboratories500124Pharmaceuticals
Dr. Reddy's expected to report a weak year-on-year Q2 with revenue and profit declines, though sequential improvement anticipated
By ScoutQuest · · 1 min read
- Expected revenue change YoY
- -2 percent
- Expected EBIT change YoY
- -45 percent
- Expected margin
- 15 percent
- Last year margin
- 26 percent
- Expected net profit change YoY
- -51 percent
Heard on business television between 15:22:05 - 15:25:05 IST.
- Revenue may fall 2% year-on-year while EBIT may fall 45% year-on-year; margin expected at around 15% versus 26% last year.
- Net profit may fall 51% year-on-year.
- Sequential improvement in revenue and profitability is expected.
- India business expected to grow 14 to 18% year-on-year; emerging markets expected to grow strongly.
- North America business expected to see pressure with degrowth of around 32 to 35% year-on-year.
Watch at source
behind live
- 1Open on YouTube
- 2Drag the seek bar left
- 3Watch this moment
Also from Dr Reddys Laboratories
Dr Reddy's files audio and video recordings of October 23, 2026 earnings call on Q2/H1 FY27 results
24 Oct 2026
Auditor's limited review reports with UDIN on Q2 and H1 results
23 Oct 2026
Board approves appointment of Akhil Ravi as Head API and Services and Senior Management Personnel
23 Oct 2026
Source: Live TV News Channel · 23 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.